questionsmedicales.fr
Enzymes et coenzymes
Enzymes
Oxidoreductases
Alcohol oxidoreductases
NAD (+) and NADP (+) dependent Alcohol oxidoreductases
3-Hydroxyacyl-CoA dehydrogenases
Hydroxymethylglutaryl-CoA reductases
Hydroxymethylglutaryl-CoA reductases : Questions médicales fréquentes
Termes MeSH sélectionnés :
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases : Questions médicales les plus fréquentes",
"headline": "Hydroxymethylglutaryl-CoA reductases : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Hydroxymethylglutaryl-CoA reductases : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-29",
"dateModified": "2025-03-26",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"url": "https://questionsmedicales.fr/mesh/D015094",
"about": {
"@type": "MedicalCondition",
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"code": {
"@type": "MedicalCode",
"code": "D015094",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA Reductases, NAD-Dependent",
"url": "https://questionsmedicales.fr/mesh/D025781",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NAD-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025781",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.250"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"alternateName": "Hydroxymethylglutaryl-CoA-Reductases, NADP-dependent",
"url": "https://questionsmedicales.fr/mesh/D025782",
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases, NADP-dependent",
"code": {
"@type": "MedicalCode",
"code": "D025782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D08.811.682.047.820.150.415.750"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Hydroxymethylglutaryl-CoA reductases",
"alternateName": "Hydroxymethylglutaryl CoA Reductases",
"code": {
"@type": "MedicalCode",
"code": "D006903",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Russell A DeBose-Boyd",
"url": "https://questionsmedicales.fr/author/Russell%20A%20DeBose-Boyd",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "Youngah Jo",
"url": "https://questionsmedicales.fr/author/Youngah%20Jo",
"affiliation": {
"@type": "Organization",
"name": "Department of Molecular Genetics, UT Southwestern Medical Center, Dallas, Texas 75390-9046, USA."
}
},
{
"@type": "Person",
"name": "George Davey Smith",
"url": "https://questionsmedicales.fr/author/George%20Davey%20Smith",
"affiliation": {
"@type": "Organization",
"name": "Medical Research Council Integrative Epidemiology Unit at the University of Bristol, Bristol, United Kingdom."
}
},
{
"@type": "Person",
"name": "Hiromasa Yoshioka",
"url": "https://questionsmedicales.fr/author/Hiromasa%20Yoshioka",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan."
}
},
{
"@type": "Person",
"name": "Kenji Ohgane",
"url": "https://questionsmedicales.fr/author/Kenji%20Ohgane",
"affiliation": {
"@type": "Organization",
"name": "Institute for Quantitative Biosciences, The University of Tokyo, 1-1-1 Yayoi, Bunkyo-ku, Tokyo 113 0032, Japan. Electronic address: ohgane@rs.tus.ac.jp."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "C-Reactive Protein as a Prognostic Biomarker for Gynecologic Cancers: A Meta-Analysis.",
"datePublished": "2022-10-11",
"url": "https://questionsmedicales.fr/article/36268143",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1155/2022/6833078"
}
},
{
"@type": "ScholarlyArticle",
"name": "Regulation of Conformational Changes in C-reactive Protein Alters its Bioactivity.",
"datePublished": "2022-08-23",
"url": "https://questionsmedicales.fr/article/35997934",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s12013-022-01089-x"
}
},
{
"@type": "ScholarlyArticle",
"name": "A rapid fluorescent aptasensor for point-of-care detection of C-reactive protein.",
"datePublished": "2022-06-04",
"url": "https://questionsmedicales.fr/article/35714415",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.talanta.2022.123661"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-reactive protein and diabetic foot ulcer infections: A meta-analysis.",
"datePublished": "2022-05-07",
"url": "https://questionsmedicales.fr/article/35581050",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.jtv.2022.05.001"
}
},
{
"@type": "ScholarlyArticle",
"name": "C-reactive protein and 10-year cardiovascular risk in rheumatoid arthritis.",
"datePublished": "2022-07-09",
"url": "https://questionsmedicales.fr/article/35821191",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.ejim.2022.07.001"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Enzymes et coenzymes",
"item": "https://questionsmedicales.fr/mesh/D045762"
},
{
"@type": "ListItem",
"position": 3,
"name": "Enzymes",
"item": "https://questionsmedicales.fr/mesh/D004798"
},
{
"@type": "ListItem",
"position": 4,
"name": "Oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D010088"
},
{
"@type": "ListItem",
"position": 5,
"name": "Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D000429"
},
{
"@type": "ListItem",
"position": 6,
"name": "NAD (+) and NADP (+) dependent Alcohol oxidoreductases",
"item": "https://questionsmedicales.fr/mesh/D064430"
},
{
"@type": "ListItem",
"position": 7,
"name": "3-Hydroxyacyl-CoA dehydrogenases",
"item": "https://questionsmedicales.fr/mesh/D015094"
},
{
"@type": "ListItem",
"position": 8,
"name": "Hydroxymethylglutaryl-CoA reductases",
"item": "https://questionsmedicales.fr/mesh/D006903"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Hydroxymethylglutaryl-CoA reductases - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment diagnostiquer une dysfonction des réductases ?\nQuels examens sont recommandés pour évaluer les réductases ?\nLes tests génétiques sont-ils utiles ?\nQuels symptômes indiquent un problème avec les réductases ?\nComment évaluer l'activité des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein&page=3#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les symptômes d'une hypercholestérolémie ?\nComment se manifeste une maladie liée aux réductases ?\nY a-t-il des signes cutanés associés ?\nLes symptômes sont-ils toujours présents ?\nQuels autres symptômes peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein&page=3#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Hydroxymethylglutaryl-CoA reductases",
"description": "Comment prévenir les problèmes liés aux réductases ?\nLe tabagisme influence-t-il les réductases ?\nL'alcool a-t-il un impact sur le cholestérol ?\nLes contrôles médicaux réguliers sont-ils importants ?\nQuels aliments privilégier pour la santé des réductases ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein&page=3#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?\nY a-t-il des traitements non médicamenteux ?\nComment les statines agissent-elles ?\nLes traitements sont-ils efficaces à long terme ?\nQuels effets secondaires peuvent survenir ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein&page=3#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quelles complications peuvent survenir avec une dyslipidémie ?\nComment l'athérosclérose est-elle liée aux réductases ?\nLes maladies hépatiques sont-elles une complication ?\nQuels risques cardiovasculaires sont associés ?\nLes complications sont-elles réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein&page=3#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Hydroxymethylglutaryl-CoA reductases",
"description": "Quels sont les principaux facteurs de risque ?\nL'hérédité joue-t-elle un rôle ?\nLe stress influence-t-il les niveaux de cholestérol ?\nL'âge est-il un facteur de risque ?\nLes maladies chroniques influencent-elles le risque ?",
"url": "https://questionsmedicales.fr/mesh/D006903?mesh_terms=C-Reactive+Protein&page=3#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction des réductases ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins mesurant les niveaux de cholestérol et des enzymes hépatiques sont effectués."
}
},
{
"@type": "Question",
"name": "Quels examens sont recommandés pour évaluer les réductases ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une échographie abdominale et des tests de fonction hépatique peuvent être recommandés."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils peuvent identifier des mutations génétiques affectant les réductases."
}
},
{
"@type": "Question",
"name": "Quels symptômes indiquent un problème avec les réductases ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des niveaux élevés de cholestérol et des maladies cardiovasculaires peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Comment évaluer l'activité des réductases ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests enzymatiques spécifiques peuvent mesurer l'activité des hydroxyméthylglutaryl-CoA réductases."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une hypercholestérolémie ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des douleurs thoraciques, fatigue et problèmes cardiaques."
}
},
{
"@type": "Question",
"name": "Comment se manifeste une maladie liée aux réductases ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elle peut se manifester par des dépôts de cholestérol dans les artères et des douleurs."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des xanthomes peuvent apparaître, indiquant une accumulation de lipides."
}
},
{
"@type": "Question",
"name": "Les symptômes sont-ils toujours présents ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Non, certains patients peuvent être asymptomatiques malgré des niveaux élevés de cholestérol."
}
},
{
"@type": "Question",
"name": "Quels autres symptômes peuvent survenir ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des troubles de la vision et des douleurs abdominales peuvent également se manifester."
}
},
{
"@type": "Question",
"name": "Comment prévenir les problèmes liés aux réductases ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée et l'exercice régulier aident à maintenir un bon cholestérol."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il les réductases ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme augmente le risque de dyslipidémie et de maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "L'alcool a-t-il un impact sur le cholestérol ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une consommation excessive d'alcool peut aggraver les niveaux de cholestérol."
}
},
{
"@type": "Question",
"name": "Les contrôles médicaux réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, ils permettent de détecter précocement les anomalies du cholestérol."
}
},
{
"@type": "Question",
"name": "Quels aliments privilégier pour la santé des réductases ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les aliments riches en fibres, comme les fruits et légumes, sont bénéfiques."
}
},
{
"@type": "Question",
"name": "Quels médicaments sont utilisés pour traiter les dysfonctionnements ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les statines sont couramment prescrites pour réduire le cholestérol sanguin."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements non médicamenteux ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des changements de mode de vie comme l'alimentation et l'exercice sont recommandés."
}
},
{
"@type": "Question",
"name": "Comment les statines agissent-elles ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Elles inhibent l'hydroxyméthylglutaryl-CoA réductase, réduisant ainsi la production de cholestérol."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils efficaces à long terme ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, avec un suivi régulier, les traitements peuvent maintenir des niveaux de cholestérol sains."
}
},
{
"@type": "Question",
"name": "Quels effets secondaires peuvent survenir ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des douleurs musculaires et des troubles digestifs sont des effets secondaires possibles."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec une dyslipidémie ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent les maladies cardiaques, les AVC et l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Comment l'athérosclérose est-elle liée aux réductases ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une production excessive de cholestérol due à des réductases dysfonctionnelles peut provoquer l'athérosclérose."
}
},
{
"@type": "Question",
"name": "Les maladies hépatiques sont-elles une complication ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une accumulation de lipides peut entraîner des maladies hépatiques comme la stéatose."
}
},
{
"@type": "Question",
"name": "Quels risques cardiovasculaires sont associés ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les niveaux élevés de cholestérol augmentent le risque de crises cardiaques et d'AVC."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être réversibles avec un traitement approprié et des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'obésité, le tabagisme, l'inactivité physique et une mauvaise alimentation."
}
},
{
"@type": "Question",
"name": "L'hérédité joue-t-elle un rôle ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de dyslipidémie augmentent le risque de problèmes liés aux réductases."
}
},
{
"@type": "Question",
"name": "Le stress influence-t-il les niveaux de cholestérol ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut contribuer à des niveaux de cholestérol élevés."
}
},
{
"@type": "Question",
"name": "L'âge est-il un facteur de risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de dyslipidémie augmente avec l'âge, surtout après 45 ans."
}
},
{
"@type": "Question",
"name": "Les maladies chroniques influencent-elles le risque ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des maladies comme le diabète augmentent le risque de dyslipidémie et de complications."
}
}
]
}
]
}
The prognostic role of CRP (C-reactive protein) in gynecological tumors has been previously reported in individual studies, but whether CRP can be used as a separate potential prognostic factor has no...
A systematic search was carried out to find the literature evaluating the predictive role of CRP in the prognosis of gynecological cancer patients. For the purpose of determining the relationship betw...
A total of 19 studies, including 4062 patients, were analyzed retrospectively. The FIGO stage was related to the CRP level (OR = 0.43, 95% CI: 0.19-1.00). Age, lymph node metastasis, and histological ...
CRP may be utilized as a prognostic indicator for a variety of gynecologic malignancies, including cervical cancer, ovarian cancer, endometrial cancer, and vulvar cancer....
The acute phase C-reactive protein (CRP) is mainly synthesized and secreted by the liver in a cytokine-mediated response to infection or inflammation and circulates as a pentamer (pCRP) in plasma. Rec...
In this paper, we report on a novel fluorescent aptasensor based on aptamers modified by both nitrogen-doped graphene quantum dots (N-GQDs) and gold nanoparticles (AuNPs) for the detection of C-reacti...
Accurate identification of diabetic foot ulcer infection (IDFU) through inflammatory markers is still a challenge in clinical practice....
This meta-analysis aims to investigates whether there is a significant indigenous association between CRP level and diabetic foot ulcer infection....
The studies on the diagnosis of IDFU by inflammatory marker C-reactive protein published before November 2021 in PubMed, Web of Science, Embase, and Cochrane Library were searched. Since the included ...
Finally, we included seven articles and investigated 592 patients, including 362 patients with IDFU and 230 patients without diabetic foot ulcer infection (NIDFU). Seven studies assessed the results o...
Meta-analysis showed a clear association between C-reactive protein and IDFU. Understanding the pathophysiology of IDFU and rapid identification of risk factors for reducing patient burdens, amputatio...
To evaluate the association between C-reactive protein (CRP) and 10-year risk of cardiovascular (CV) events using the Expanded Cardiovascular Risk Prediction Score for Rheumatoid Arthritis (ERS-RA), b...
ERS-RA was calculated in 1,251 "Cardiovascular Obesity and Rheumatic Disease Study (CORDIS)" database patients [(age 60.4(9.3) years; 78% female; disease duration, 11.6(8) years; CDAI, 9(9); CRP, 6.8(...
The mean (SD) 10-year risk of CV events was 12.9% (10). After adjusting for the use of DMARDs and biologics, CRP concentrations were significantly associated with 10-year risk of CV events (coefficien...
In a large cohort of RA patients without previous cardiovascular events, a 20 mg/L increase in CRP concentrations was associated with a 1% increase in 10-year risk of CV events. This suggests that act...
Chronic hepatitis C (CHC) is one of the most important health problems affecting the significant rate of world population and it may lead to cirrhosis and hepatocellular carcinoma. C-reactive protein ...
Patients with CHC infection who visited outpatient and inpatient internal medicine clinics of our institution between January 2021 and December 2021 were enrolled to this retrospective study. CLR of t...
Median CLR of CHC and control subjects was 2.61 (5.13%) and 0.31 (0.37%), respectively. CLR of the CHC group was significantly increased compared to the CLR of the controls (p<0.001). There was a sign...
Increased CLR in patients with CHC may be an alarming finding of liver fibrosis, as CLR is associated with both CHC and hepatic fibrosis....
Life's Essential 8 (LE8) is a score that includes modifiable risk factors for cardiovascular disease. Four health behaviors (diet, physical activity, nicotine exposure and sleep health) and four healt...
We investigate the interactions between C-reactive protein (CRP) and new CRP-binding peptide materials using experimental (biological and physicochemical) methods with the support of theoretical simul...
To assess whether low-grade inflammation, measured by serum high-sensitivity C-reactive protein (hsCRP) levels, is associated with...
A retrospective study....
University-affiliated IVF center....
In the present study, 875 women of normal weight who underwent their first fresh embryo transfer (ET) cycles for IVF treatment were divided into three groups according to serum concentrations of hsCRP...
Serum from women undergoing IVF was collected on days 2-4 of a spontaneous menstrual cycle prior to the commencement of ovarian stimulation....
The IVF outcomes included implantation, biochemical pregnancy, clinical pregnancy, miscarriage and live birth rates....
The women were divided into three groups according to the baseline serum levels of hsCRP as follows: low hsCRP (<1 mg/L; n=517), medium hsCRP (1-3 mg/L; n= 270), high hsCRP (>3 mg/L; n=88). The matern...
Among women of normal weight undergoing their first IVF treatment, it was found that low-grade inflammation was associated with reduced clinical pregnancy and live birth rates following fresh ET cycle...
Interest in using bedside C-reactive protein (CRP) and ferritin levels to identify patients with hyperinflammatory sepsis who might benefit from anti-inflammatory therapies has piqued with the COVID-1...
A prospective, observational cohort study....
Children with sepsis and organ failure in nine pediatric intensive care units in the United States....
Two hundred and fifty-five children were enrolled. Five distinct clinical multi-trajectory groups were identified. Plasma CRP (mg/dL), ferritin (ng/mL), and 31 cytokine levels were measured at two tim...
Group 1 had normal CRP and ferritin levels ( n = 8; 0% mortality); Group 2 had high CRP levels that became normal, with normal ferritin levels throughout ( n = 80; 5% mortality); Group 3 had high ferr...
Bedside CRP and ferritin levels can be used together to distinguish groups of children with sepsis who have different systemic inflammation cytokine responses and mortality risks. These data suggest f...